Lilly Acquires Morphic Holding, Inc. for $3.2 Billion
On July 8, Lilly (formally known as Eli Lilly and Company) announced that it acquired Morphic Holding, Inc. for an estimated $3.2 billion. Lilly plans to acquire all outstanding shares of Morphic for $57 per share in cash. The purchase price at closing is a premium of around 79% to the closing stock price on Friday. Morphic Holding is a Massachusetts-based biotechnology company that is leading the development of new oral integrin drugs for inflammatory bowel diseases. Its proprietary MInT drug discovery platform combines an expert understanding of integrin dynamics and analytical capabilities with foundational structural biology insights and ongoing input from the Massachusetts-based... Read More »
Pentixapharm Acquires Glycotope’s Target Discovery Unit
On July 3, Pentixapharm announced that it entered into an agreement to acquire certain discovery assets from Glycotope, a Berlin, Germany-based biotechnology company. The assets are aimed at various oncology targets and could be turned into radiopharmaceuticals. Pentixapharm is a radiopharmaceutical development company founded in 2019, with its headquarters in Würzburg, Germany. It develops PentixaFor and PentixaTher, two small peptide-based radiopharmaceuticals that specifically target the CXCR4-receptor expressed in hematological and solid cancers, as well as cardiovascular and endocrine diseases. This acquisition is aimed at doubling Pentixapharm’s pipeline of... Read More »
Johnson & Johnson Acquires Proteologix for $850 Million
On May 16 Johnson & Johnson (J&J) announced that it acquired Proteologix, Inc. for $850 million. Proteologix is privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases. Proteologix’s portfolio includes PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to enter phase 1 development for moderate to severe atopic dermatitis (AD) and moderate to severe asthma, and PX130, a bispecific antibody targeting IL-13 plus IL-22, which is in preclinical development for moderate to severe AD. J&J is one of the largest global healthcare and pharmaceutical companies with more than 130,000 employees worldwide. Its... Read More »
Arbor Biotechnologies Acquires Serendipity
Arbor Biotechnologies announced on May 8 that it entered into an agreement to acquire Serendipity Biosciences. The financial terms were not disclosed. Serendipity Biosciences is a private biotechnology company focused on the discovery of unique gene editing technologies. Serendipity’s novel editing technologies were discovered in the lab of leading gene editing researcher and Arbor Biotechnologies co-founder, Feng Zhang, of the McGovern Institute for Brain Research at MIT and the Broad Institute of MIT and Harvard. Arbor Biotechnologies is a next-generation gene editing biotechnology company based in Cambridge, Massachusetts. It is focused on discovering and developing... Read More »
Deciphera Pharmaceuticals to be Acquired by Ono Pharmaceutical for $2.4 Billion
Deciphera Pharmaceuticals announced on April 29 that it has entered into a definitive merger agreement with Ono Pharmaceutical Co., Ltd. Ono will acquire all outstanding shares of Deciphera common stock for $25.60 per share in cash through a tender offer followed by a merger of Deciphera with a wholly-owned subsidiary of Ono, for a total equity value of $2.4 billion. Deciphera Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
